AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific SessionsBusiness Wire • 05/06/24
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset DivestitureBusiness Wire • 04/04/24
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PEBusiness Wire • 04/04/24
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.Business Wire • 04/01/24
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 03/28/24
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024Business Wire • 03/19/24
AngioDynamics (ANGO) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 03/15/24
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services ConferenceBusiness Wire • 03/06/24
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market TodayZacks Investment Research • 02/23/24
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 MillionBusiness Wire • 02/15/24
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial DiseaseBusiness Wire • 01/23/24